Blood-Based RNA Signature May Predict Alzheimer’s Symptoms Years Before Onset
In a study involving nearly 2,400 participants, a 34-circular RNA signature outperformed plasma pTau217 in predicting progression to symptomatic Alzheimer's disease.
In a study involving nearly 2,400 participants, a 34-circular RNA signature outperformed plasma pTau217 in predicting progression to symptomatic Alzheimer's disease.
The assay identifies patients with microsatellite instability-high solid tumors who may be eligible for treatment with the immunotherapy.
The FDA has cleared Cepheid’s Xpert Hemorrhagic Fever Panel, a multiplex PCR test that detects four hemorrhagic fever viruses and delivers results in about an hour on GeneXpert Dx systems, according to the company.
Genefluence’s near-patient test identifies UTI-causing bacteria and antibiotic resistance genes in approximately one hour, potentially helping clinicians make faster treatment decisions.
Read MoreThe RNA-based panel detects leukemia-associated gene fusions at levels as low as 1% tumor cells, offering another approach to monitoring residual disease.
Read MoreThe test monitors circulating tumor DNA without requiring tumor tissue profiling, with clinical study findings showing detection of disease progression a median of 7.4 months before imaging.
Read MoreThe funding will support clinical studies and laboratory validation of a semen-based assay that detects epigenetic changes linked to severe male infertility and potentially increased cancer risk.
Read MoreAbbott has launched a next-generation Oncodetect MRD test that uses whole-genome sequencing to track up to 5,000 patient-specific cancer variants, offering a 30-fold increase in detection sensitivity, according to the company.
Read MoreTempus AI’s xR RNA sequencing assay has received EU IVDR Class C certification, enabling continued clinical and biopharma access in the EU for gene fusion detection in solid tumors beyond the 2028 regulatory transition deadline.
Read MoreMedicare has begun reimbursing Lucid Diagnostics $1,938 per test for its EsoGuard Esophageal DNA Test under the Clinical Laboratory Fee Schedule. The company also closed a $15 million private placement to support commercialization.
Read MoreDiatech Pharmacogenetics has acquired SensoQuest and launched the Labcycler PCR thermal cycler, expanding into laboratory instrumentation with a platform rated for up to 600,000 cycles and manufactured in Italy.
Read MoreThe acquisition adds a saliva assay for periodontal pathogen detection, extending the CLIA-certified laboratory’s services to dental practices.
Read MoreThe 20-minute multiplex test delivers eight results covering bacterial vaginosis, Candida species, and trichomoniasis from clinician- or self-collected swabs.
Read MoreThe partnership will allow clinical laboratories to integrate multiple Panther Systems into automated workflows designed to increase testing capacity and improve sample tracking.
Read MoreQuest Diagnostics and Waters Corp will expand at-home HPV screening nationwide in 2027, offering extended genotyping via the FDA-cleared Onclarity Self-Collection Kit through clinical, health plan, and consumer channels.
Read MoreA study in The Journal of Molecular Diagnostics found that liquid biopsy tests can detect lung cancer recurrence months before imaging, using ctDNA analysis to monitor relapse risk in early-stage NSCLC patients.
Read MoreThe molecular test can identify multiple causes of fever from a single blood sample in about an hour, helping healthcare workers diagnose infections and respond to outbreaks more quickly.
Read MoreSOPHiA GENETICS and Myriad Genetics are collaborating to develop a decentralized prostate cancer companion diagnostic, aiming to enable local labs to assess DNA repair deficiencies using the PrGIS biomarker in clinical trials.
Read More